South & Central America Bioproduction Market Forecast to 2030
South & Central America Bioproduction Market Forecast to 2030 – Regional Analysis – by Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), and End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Patent Expiry of Blockbuster Biologics Fuels South & Central America Bioproduction Market
Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. Patents on originator biologicals are expected to expire in the coming years.
Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table.
Biologicals Expiry Dates
Avastin January 2022
Cyramza May 2023
Adcetris August 2023
Abthrax October 2024
Gazyva/Gazyvaro November 2024
Darzalex May 2026
Ocrevus April 2027
Emgality September 2028
Hemlibra February 2028
Llumetri March 2028
Imfinzi September 2028
Mylotarg April 2028
Imfinzi September 2028
Mylotarg April 2028
Sylvant July 2034
The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the bioproduction market during the forecast period.
South & Central America Bioproduction Market Overview
The bioproduction market in South & Central America is subsegmented into Brazil, Argentina, and the Rest of South & Central America. Growing developments in the medical industry and increasing awareness regarding cell therapy in Brazil are likely to create significant growth opportunities for market growth. Similarly, the growing healthcare industry in Argentina is expected to offer growth opportunities for the bioproduction market.
According to an article published in Biomaterials Research, in 2020, Brazil was among the top ten countries in the world in terms of the highest number of people having diabetes, and it currently ranks fifth. Currently, Brazil is the fifth top country in the world with the highest prevalence of diabetes mellitus (DM) in adults. According to the International Diabetes Federation (IDF), it is estimated that an increase of 54.7% of new cases of diabetes by 2045.
According to GaBI, in 2022, the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA) approved 30 biosimilars within the product classes of insulin, monoclonal antibodies, tumor necrosis factor (TNF) inhibitor, human growth hormone, anticoagulants and heparins, and granulocyte colony-stimulating factor for use in Brazil. The ANVISA approved Admelog biosimilar by Sanofi in Brazil to treat diabetes. Thus, growing diabetic cases and increasing product approvals in Brazil are driving the bioproduction market.
South & Central America Bioproduction Market Revenue and Forecast to 2030 (US$ Million)
South & Central America Bioproduction Market Segmentation
The South & Central America bioproduction market is categorized into product, application, equipment, end user, and country.
Based on product, the South & Central America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest South & Central America bioproduction market share in 2022.
In terms of application, the South & Central America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held the largest South & Central America bioproduction market share in 2022.
By equipment, the South & Central America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held the largest South & Central America bioproduction market share in 2022.
In terms of end user, the South & Central America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest South & Central America bioproduction market share in 2022.
By country, the South & Central America bioproduction market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America bioproduction market share in 2022.
Lonza Group AG, Danaher Corp, Sartorius AG, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc. are some of the leading companies operating in the South & Central America bioproduction market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to the Research Team’ research, the South & Central America bioproduction market was valued at US$ 799.67 million in 2022 and is expected to reach US$ 1,965.21 million by 2030, registering a CAGR of 11.9% from 2022 to 2030. Shift toward automated cell therapy manufacturing and increasing prevalence of chronic diseases are among the critical factors attributed to drive the South & Central America bioproduction market growth.
Automation can deliver many benefits for cell therapy developers, including reduced risk of contamination, improved consistency, and reduced cost of production. Many companies have offered devices to enable automation, such as the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. A rising number of cell therapies have shifted the production of cell therapy products from a small volume to a large volume worldwide. In addition, the evolution of cell therapy, from an academic and clinical setting to mass production and commercialization, is increasing the demand for automation in manufacturing. Increasing research activities in cell therapies have led to a rise in demand for advanced manufacturing solutions. In view of this, many players are offering products to meet the digital needs of academic researchers and large biotechnology companies. For instance, in May 2019, GE Healthcare launched the Chronicle web application to support the complete cell therapy workflow. Chronicle automation software is a good manufacturing practice (GMP)-compliant digital solution designed to optimize complex cell therapy process development and manufacturing.
Companies are also entering into strategic and technological developments for automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the fitness of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software) along with reagents, consumables, and instruments. Thus, the increasing adoption of automation among cell therapy manufacturers is anticipated to drive the market.
On the contrary, high cost of cell therapy and biosimilar manufacturing hampers the growth of South & Central America bioproduction market.
Based on product, the South & Central America bioproduction market is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held 38.2% South & Central America bioproduction market share in 2022, amassing US$ 305.71 million. It is projected to garner US$ 703.92 million by 2030 to register 11.0% CAGR during 2022-2030.
In terms of application, the South & Central America bioproduction market is segmented into rheumatoid arthritis, hematological disorders, cancer, diabetes, cardiovascular diseases, and others. The cancer segment held 36.4% share of South & Central America bioproduction market in 2022, amassing US$ 290.99 million. It is anticipated to garner US$ 744.84 million by 2030 to expand at 12.5% CAGR during 2022-2030.
By equipment, the South & Central America bioproduction market is divided into upstream equipment, downstream equipment, bioreactors, and consumables and accessories. The consumables and accessories segment held 39.9% share of South & Central America bioproduction market in 2022, amassing US$ 319.44 million. It is projected to garner US$ 829.10 million by 2030 to expand at 12.7% CAGR from 2022 to 2030.
In terms of end user, the South & Central America bioproduction market is categorized into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held 51.1% share of South & Central America bioproduction market in 2022, amassing US$ 408.83 million. It is projected to garner US$ 993.48 million by 2030 to expand at 11.7% CAGR from 2022 to 2030.
Based on country, the South & Central America bioproduction market is categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 66.5% share of South & Central America bioproduction market in 2022. It was assessed at US$ 531.38 million in 2022 and is likely to hit US$ 1,331.04 million by 2030, registering a CAGR of 12.2% during 2022-2030.
Key players operating in the South & Central America bioproduction market are Lonza Group AG, Danaher Corp, Sartorius AG, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America bioproduction market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America bioproduction market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
TABLE OF CONTENTS
1. Introduction
1.1 the Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Bioproduction Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Rising Adoption of Regenerative Medicines
4.1.2 Increasing Prevalence of Chronic Diseases
4.2 Market Restraints
4.2.1 High Cost of Cell Therapy and Biosimilar Manufacturing
4.3 Market Opportunities
4.3.1 Patent Expiry of Blockbuster Biologics
4.4 Future Trends
4.4.1 Shift Toward Automated Cell Therapy Manufacturing
4.5 Impact Analysis
5. Bioproduction Market – South & Central America Market Analysis
5.1 South & Central America Bioproduction Market Revenue (US$ Mn), 2020 – 2030
6. South & Central America Bioproduction Market – Revenue and Forecast to 2030 – by Product
6.1 Overview
6.2 South & Central America Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
6.3 Biologics and Biosimilars
6.3.1 Overview
6.3.2 Biologics and Biosimilars: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Cell and Gene Therapies
6.5.1 Overview
6.5.2 Cell and Gene Therapies: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Nucleic Acid Therapeutics
6.6.1 Overview
6.6.2 Nucleic Acid Therapeutics: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
6.7 Others
6.7.1 Overview
6.7.2 Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7. South & Central America Bioproduction Market – Revenue and Forecast to 2030 – by Application
7.1 Overview
7.2 South & Central America Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Cardiovascular Diseases
7.4.1 Overview
7.4.2 Cardiovascular Diseases: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Rheumatoid Arthritis
7.5.1 Overview
7.5.2 Rheumatoid Arthritis: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Hematological Disorders
7.6.1 Overview
7.6.2 Hematological Disorders: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.7 Diabetes
7.7.1 Overview
7.7.2 Diabetes: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
7.8 Others
7.8.1 Overview
7.8.2 Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Bioproduction Market – Revenue and Forecast to 2030 – by Equipment
8.1 Overview
8.2 South & Central America Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
8.3 Consumables and Accessories
8.3.1 Overview
8.3.2 Consumables and Accessories: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Downstream Equipment
8.4.1 Overview
8.4.2 Downstream Equipment: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Bioreactors
8.5.1 Overview
8.5.2 Bioreactors: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
8.5.2.1 South & Central America: Bioproduction Market, For Bioreactors by Equipment, 2020-2030 (US$ Million)
8.6 Upstream Equipment
8.6.1 Overview
8.6.2 Upstream Equipment: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Bioproduction Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 South & Central America Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Biopharmaceutical Companies
9.3.1 Overview
9.3.2 Biopharmaceutical Companies: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Contract Manufacturing Organizations
9.4.1 Overview
9.4.2 Contract Manufacturing Organizations: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Bioproduction Market – Revenue and Forecast to 2030 – Country Analysis
10.1 South & Central America: Bioproduction Market
10.1.1 South & Central America: Bioproduction Market Share by Country – 2022 & 2030, (%)
10.1.1.1 Brazil: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2 Brazil: Bioproduction Market- Revenue and Forecasts to 2030 (US$ Million)
10.1.1.2.1 Brazil: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.2.2 Brazil: Bioproduction Market, By Application, 2020-2030 (US$ Million)
10.1.1.2.3 Brazil: Bioproduction Market, By Equipment, 2020-2030 (US$ Million)
10.1.1.2.3.1 Brazil: Bioproduction Market, for Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.2.4 Brazil: Bioproduction Market, By End User, 2020-2030 (US$ Million)
10.1.1.3 Argentina: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.4 Argentina: Bioproduction Market- Revenue and Forecasts to 2030 (US$ Million)
10.1.1.4.1 Argentina: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.4.2 Argentina: Bioproduction Market, By Application, 2020-2030 (US$ Million)
10.1.1.4.3 Argentina: Bioproduction Market, By Equipment, 2020-2030 (US$ Million)
10.1.1.4.3.1 Argentina: Bioproduction Market, for Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.4.4 Argentina: Bioproduction Market, By End User, 2020-2030 (US$ Million)
10.1.1.5 Rest of South & Central America: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.6 Rest of South & Central America: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Rest of South & Central America: Bioproduction Market, by Product, 2020-2030 (US$ Million)
10.1.1.6.2 Rest of South & Central America: Bioproduction Market, By Application, 2020-2030 (US$ Million)
10.1.1.6.3 Rest of South & Central America: Bioproduction Market, By Equipment, 2020-2030 (US$ Million)
10.1.1.6.3.1 Rest of South & Central America: Bioproduction Market, for Bioreactors by Equipment, 2020-2030 (US$ Million)
10.1.1.6.4 Rest of South & Central America: Bioproduction Market, By End User, 2020-2030 (US$ Million)
11. Bioproduction Market-Industry Landscape
11.1 Overview
11.2 Growth Strategies in the Bioproduction Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Lonza Group AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Danaher Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Sartorius AG
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Thermo Fisher Scientific Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Merck KGaA
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 F. Hoffmann-La Roche Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Bio-Rad Laboratories Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms
LIST OF TABLES
Table 2. South & Central America Bioproduction Market, For Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 3. Brazil: Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 4. Brazil: Bioproduction Market, By Application – Revenue and Forecast to 2030 (US$ Million)
Table 5. Brazil: Bioproduction Market, By Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 6. Brazil: Bioproduction Market, for Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 7. Brazil: Bioproduction Market, By End User – Revenue and Forecast to 2030 (US$ Million)
Table 8. Argentina: Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 9. Argentina: Bioproduction Market, By Application – Revenue and Forecast to 2030 (US$ Million)
Table 10. Argentina: Bioproduction Market, By Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 11. Argentina: Bioproduction Market, for Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 12. Argentina: Bioproduction Market, By End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Rest of South & Central America: Bioproduction Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. Rest of South & Central America: Bioproduction Market, By Application – Revenue and Forecast to 2030 (US$ Million)
Table 15. Rest of South & Central America: Bioproduction Market, By Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 16. Rest of South & Central America: Bioproduction Market, for Bioreactors by Equipment – Revenue and Forecast to 2030 (US$ Million)
Table 17. Rest of South & Central America: Bioproduction Market, By End User – Revenue and Forecast to 2030 (US$ Million)
Table 18. Recent Inorganic Growth Strategies in the Bioproduction Market
Table 19. Recent Organic Growth Strategies in the Bioproduction Market
Table 20. Glossary of Terms, Bioproduction Market
Â
LIST OF FIGURES
Figure 2. South & Central America Bioproduction Market: Key Industry Dynamics
Figure 3. South & Central America Bioproduction Market: Impact Analysis of Drivers and Restraints
Figure 4. South & Central America Bioproduction Market Revenue (US$ Mn), 2020 – 2030
Figure 5. South & Central America Bioproduction Market Revenue Share, by Product 2022 & 2030 (%)
Figure 6. Biologics and Biosimilars: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Vaccines: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Cell and Gene Therapies: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Nucleic Acid Therapeutics: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. South & Central America Bioproduction Market Revenue Share, by Application 2022 & 2030 (%)
Figure 12. Cancer: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Cardiovascular Diseases: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Rheumatoid Arthritis: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Hematological Disorders: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Diabetes: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. South & Central America Bioproduction Market Revenue Share, by Equipment 2022 & 2030 (%)
Figure 19. Consumables and Accessories: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Downstream Equipment: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Bioreactors: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 22. Upstream Equipment: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. South & Central America Bioproduction Market Revenue Share, by End User 2022 & 2030 (%)
Figure 24. Biopharmaceutical Companies: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Contract Manufacturing Organizations: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 26. Others: South & Central America Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 27. South & Central America: Bioproduction Market, By Key Country – Revenue (2022) (US$ Million)
Figure 28. South & Central America: Bioproduction Market Share by Country – 2022 & 2030, (%)
Figure 29. Brazil: Bioproduction Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 30. Argentina: Bioproduction Market- Revenue and Forecasts to 2030 (US$ Million)
Figure 31. Rest of South & Central America: Bioproduction Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Growth Strategies in the Bioproduction Market
1. Lonza Group AG
2. Danaher Corp
3. Sartorius AG
4. Thermo Fisher Scientific Inc
5. Merck KGaA
6. F. Hoffmann-La Roche Ltd
7. Bio-Rad Laboratories Inc
You must be logged in to post a review.
Reviews
There are no reviews yet.